
|Videos|December 20, 2022
Dr. Dorff on state of second-line treatment for metastatic urothelial cancer
Author(s)Urology Times staff
Advertisement
Tanya Dorff, MD, discusses the currently available therapeutic options for patients with metastatic urothelial cancer who have progressed on frontline treatment. Dorff is a medical oncologist, section chief of Genitourinary Disease Program, and associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
AI-generated profiles impersonate female urologists to market ED products online
2
Alternative BCG strains may help address ongoing supply challenges in NMIBC
3
Doublet or triplet? Urologists weighs in on mCSPC options
4
Pearls & Perspectives: Sexual Health and Intimacy in Midlife, With Karen Bigman, MBA
5






